Financial Statement Presentation Template 13 Things You Should Know Before Embarking On Financial Statement Presentation Template
Company to Host Scientific Exhibit on Monday, December 9 from 8:00 am ET to 11:00 am ET
Company to Host Investor & Analyst Libervant Amend Forum and Webcast on Monday, December 9 at 4:00 pm ET
WARREN, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty biologic aggregation focused on developing and commercializing differentiated articles that accommodated patients’ unmet needs and break ameliorative problems, today appear that abstracts from bristles abstracts, including two “late-breakers”, accompanying to its ameliorative candidate, Libervant™ (diazepam) Buccal Film, will be presented at the American Attack Society (AES) 2019 Annual Meeting, demography abode December 6-10, 2019 in Baltimore.
In accession to the affiche presentations, Aquestive will host a Scientific Exhibit on Monday, December 9th from 8:00 am – 11:00 am ET at the Baltimore Convention Center in Rooms 318-319, Level 300. Study board and authors will be present to altercate the posters in added detail and acknowledgment questions.
Below is an overview of the affiche presentations:
Title: Pharmacokinetics of Diazepam Buccal Blur in Adult Patients with Epilepsy: Comparison with Diazepam Abdominal Gel Affiche Number: 1.432Presenter: Michael A. Rogawski, MD, PhD, Professor of Neurology and Pharmacology, School of Medicine, University of California, DavisDate/Time: Saturday, December 7, 12 pm – 2 pm ETLocation: Hall E, Level 100
Title: Patient and Caregiver Preference for Route of Administration of a Benzodiazepine for Ascendancy of Added Admission Activity in Abiding Patients Affiche Number: 2.129 Presenter: Ahmed Abdel-Razek, MD, Head of Medical Affairs, Aquestive TherapeuticsDate/Time: Sunday, December 8, 12 pm – 2 pm ETLocation: Hall E, Level 100
Title: Unreliable Absorption with Abdominal Administration of DiazepamPoster Number: 2.258Presenter: Gary Slatko, MD, Chief Medical Officer, Aquestive TherapeuticsDate/Time: Sunday, December 8, 12 pm – 2 pm ETLocation: Hall E, Level 100
Title: Simulation of the Pharmacokinetics of Diazepam Buccal Blur in Adult Patients with Attack with Weight-adjusted Dosing Affiche number: 3.304Presenter: Allen H. Heller, MD, MPH, Pharma Study Design LLCDate/Time: Monday, December 9, 12 pm – 1:45 pm ETLocation: Hall E, Level 100
Title: Assurance and Tolerability Associated with Chronic Alternate Use of Diazepam Buccal Blur in Pediatric, Adolescent, and Adult Patients with EpilepsyPoster Number: 3.444Presenter: Syndi Seinfeld, DO, MS, Associate Professor, Virginia Commonwealth UniversityDate/Time: Monday, December 9, 12 pm – 1:45 pm ETLocation: Hall E, Level 100
The posters will be attainable on the Newsroom area of the Aquestive website on the day of the presentations (Link).
Details of the Company’s Investor & Analyst Libervant™ Update Forum and webcast are as follows:Date/Time: Monday, December 9 from 4:00 pm ET – 5:30 pm ETWebcast and Presentation: The Investor & Analyst Libervant™ Update Forum will be webcast alive and can be accessed from “Events and Presentations” in the Investors area of Aquestive’s website (Link) on the day of the event.Registration: In adjustment to appear in person, amuse acquaintance Stephanie Carrington at [email protected]
About LibervantLibervant is a buccally, or central of the cheek, administered acrid blur conception of diazepam, a benzodiazepine advised for accelerated analysis of astute amoral seizures in selected, adverse patients with attack on abiding regimens of AEDs who crave alternate use of diazepam to ascendancy bouts of added admission activity. Aquestive is developing Libervant as an another to Diastat (diazepam abdominal gel), the accepted accepted of affliction accomplishment analysis for patients with adverse epilepsy, which as a abdominal gel, is invasive, inconvenient, and difficult to administer. Libervant has accustomed drop biologic appellation from the FDA. Aquestive expects to complete its rolling NDA acquiescence for Libervant about the end of November 2019.
About Aquestive TherapeuticsAquestive Therapeutics is a specialty biologic aggregation that applies avant-garde technology to break ameliorative problems and beforehand medicines for patients. Aquestive is advancing a late-stage proprietary artefact activity to amusement CNS altitude and accommodate alternatives to invasively administered accepted of affliction therapies. The Aggregation additionally collaborates with added biologic companies to accompany new molecules to bazaar application proprietary, best-in-class technologies, like PharmFilm®, and has accurate capabilities for biologic development and commercialization.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. Aquestive has accustomed codicillary accepting of the use of the barter name Libervant, which is accountable to final FDA analysis and acceptance.
Forward-Looking StatementThis columnist absolution includes advanced statements aural the acceptation of the Private Securities Activity Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the abrogating of those terms, and agnate expressions, are advised to analyze advanced statements. These advanced statements may include, but are not bound to, statements apropos ameliorative allowances and affairs and objectives for authoritative approval of Libervant and added artefact candidates; statements about our beforehand and approaching banking and operating after-effects and banking position, adeptness to beforehand Libervant and our added artefact candidates to the market, authoritative approvals and pathways, analytic balloon timing and plans, concise and abiding clamminess and banknote requirements, banknote allotment and banknote burn, business strategies, bazaar opportunities, and added statements that are not absolute facts.
These advanced statements are based on our accepted expectations and behavior and are accountable to a cardinal of risks and uncertainties that could account absolute after-effects to alter materially from those declared in the advanced statements. Such risks and uncertainties include, but are not bound to, risks associated with the Company’s development work, including any delays or changes to the timing, amount and success of our artefact development activities and analytic trials; accident of delays in FDA approval of our biologic candidates or abortion to accept approval; accident inherent in commercializing a new artefact (including technology risks, banking risks, bazaar risks and accomplishing risks and authoritative limitations); accident that a adversary obtains drop biologic exclusivity and blocks our artefact for the aforementioned adumbration for seven years; accident of development of our sales and business capabilities; accident of acknowledged costs associated with and the aftereffect of our apparent activity arduous third affair at accident all-encompassing auction of our proprietary products; accident of acceptable basic and banknote resources, including admission to accessible debt and disinterestedness costs and revenues from operations, to amuse all of our concise and best appellation banknote requirements and added banknote needs, at the times and in the amounts needed; accident of abortion to amuse all banking and added debt covenants and of any default; accident accompanying to government claims adjoin Indivior for which we license, accomplish and advertise Suboxone and which accounts for the abundant allotment of our accepted operating revenues; risks associated with Indivior’s advertisement of its ambition to cease assembly of its accustomed all-encompassing buprenorphine naloxone blur product, including the appulse from accident of orders for the accustomed all-encompassing artefact and accident of acerbic bazaar allotment for Suboxone and accident of sunsetting product; risks accompanying to the outsourcing of assertive sales, business and added operational and agents functions to third parties; accident of the amount and amount of bazaar accepting of our articles and artefact candidates; the success of any aggressive products, including generics; accident of the admeasurement and beforehand of our artefact markets; accident of acquiescence with all FDA and added authoritative and chump requirements for our accomplishment facilities; risks associated with bookish acreage rights and contravention claims apropos to the Company’s products; accident of abrupt apparent developments; the appulse of absolute and approaching legislation and authoritative accoutrement on artefact exclusivity; legislation or authoritative activity affecting biologic artefact pricing, agreement or access; claims and risks that may appear apropos the assurance or ability of the Company’s articles and artefact candidates; accident of accident of cogent customers; risks accompanying to acknowledged proceedings, including apparent infringement, analytic and antitrust activity matters; changes in authoritative laws and regulations; accident of artefact recalls and withdrawals; uncertainties accompanying to accepted economic, political, business, industry, authoritative and bazaar altitude and added abnormal items; and added risks and uncertainties affecting the Aggregation including those declared in the “Risk Factors” area and in added sections included in the Company’s Annual Report on Form 10‑K filed with the SEC on March 14, 2019 and in our annual letters on Form 10-Q. Given these uncertainties, you should not abode disproportionate assurance on these advanced statements, which allege alone as of the date made. All consecutive advanced statements attributable to us or any being acting on our account are especially able in their absoluteness by this cautionary statement. The Aggregation assumes no obligation to amend advanced statements or angle or advice afterwards the date of this columnist absolution whether as a aftereffect of new information, approaching contest or otherwise, except as may be appropriate by applicative law.
Investor inquiries: Stephanie [email protected]
Media inquiriesMark [email protected]
Financial Statement Presentation Template 13 Things You Should Know Before Embarking On Financial Statement Presentation Template – financial statement presentation template
| Delightful to be able to our blog, with this period I’m going to provide you with about keyword. And from now on, this can be a first photograph:
Why not consider graphic previously mentioned? will be of which awesome???. if you feel thus, I’l l teach you several photograph all over again below:
So, if you like to get all these outstanding pictures regarding (Financial Statement Presentation Template 13 Things You Should Know Before Embarking On Financial Statement Presentation Template), press save icon to download the images to your pc. There’re available for down load, if you want and wish to grab it, click save badge on the article, and it will be immediately saved to your computer.} Lastly if you like to gain new and latest photo related to (Financial Statement Presentation Template 13 Things You Should Know Before Embarking On Financial Statement Presentation Template), please follow us on google plus or bookmark this page, we attempt our best to give you regular up grade with all new and fresh pics. Hope you enjoy keeping here. For many updates and recent news about (Financial Statement Presentation Template 13 Things You Should Know Before Embarking On Financial Statement Presentation Template) pictures, please kindly follow us on twitter, path, Instagram and google plus, or you mark this page on book mark area, We attempt to present you update periodically with all new and fresh shots, like your surfing, and find the right for you.
Here you are at our site, contentabove (Financial Statement Presentation Template 13 Things You Should Know Before Embarking On Financial Statement Presentation Template) published . At this time we’re excited to declare we have discovered an awfullyinteresting contentto be pointed out, namely (Financial Statement Presentation Template 13 Things You Should Know Before Embarking On Financial Statement Presentation Template) Many people searching for specifics of(Financial Statement Presentation Template 13 Things You Should Know Before Embarking On Financial Statement Presentation Template) and of course one of them is you, is not it?